AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Rare Disease (Alexion) — Worldwide product sales by Quarter
Rare Disease (Alexion) — Worldwide product sales ($M) ($M)
AstraZeneca Rare Disease (Alexion) — Worldwide product sales: $2,490M in Q2 2026, up 8.5% from a year earlier. That is the highest of the 20 quarters on record here.
Where the Q2 2026 figure comes from
“|| Rare Disease | | 2,490 | | 9 | | 8 | | 1,452 | | 8 | | 305 | | 10 | | 6 | | 442 | | 7 | | 3 | | 291 | | 13 | | 20”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up rare Disease (Alexion) — Worldwide product sales
- Rare Disease (Alexion) — Worldwide YoY actual (%)9.0% · Q2 2026
- Rare Disease (Alexion) — Worldwide YoY CER (%)8.0% · Q2 2026
- Rare Disease (Alexion) — US product sales ($M)1,452 · Q2 2026
- Rare Disease (Alexion) — Emerging Markets product sales ($M)305 · Q2 2026
- Rare Disease (Alexion) — Europe product sales ($M)442 · Q2 2026
- Rare Disease (Alexion) — Established RoW product sales ($M)291 · Q2 2026
- Ultomiris (ravulizumab) — Worldwide product sales ($M)1,314 · Q2 2026
- Soliris (eculizumab) — Worldwide product sales ($M)389 · Q2 2026
- Strensiq (asfotase alfa) — Worldwide product sales ($M)536 · Q2 2026
- Koselugo (selumetinib) — Worldwide product sales ($M)177 · Q2 2026
- Other Rare Disease medicines — Worldwide product sales ($M)74 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Rare Disease (Alexion) — Worldwide product sales ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-rare-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.